Navigation Links
Elan Pharmaceuticals Joins GeneGo's MetaTox Consortium
Date:11/27/2007

ST. JOSEPH, Mich., Nov. 27 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Elan Pharmaceuticals has joined the MetaTox Consortium. The Consortium, led by Dr. Richard Brennan, will be focused on developing systems biology tools for safety assessment of small molecule compounds and biological therapeutics. This effort will include expanding the existing tools in the MetaDiscovery(TM) platform with toxicity ontologies, developing "knowledge-based" predictive models (functional descriptors), manual reconstruction of toxicity pathways in human and relevant preclinical model species, and the development of simplified workflows for analyzing and reporting systems toxicology data. These tools, unique to the marketplace, will enable the members to leverage their diverse molecular toxicology data in an integrated "systems" perspective that has not been available until now.

"The MetaTox Consortium is a cost effective vehicle for the members to develop software and expand content in systems toxicology," said Julie Bryant, Vice President of Business Development for GeneGo. "The Consortium will propose the deliverables, to be voted on and prioritized by the members, and GeneGo will then develop and deliver the agreed-upon content and software with members' input. All the members joining to date have said that they could not perform this amount of work internally for the membership fee, which helped to justify the business model."

"Despite the increasing deployment of new technologies probing the molecular basis of chemical toxicity, too many investigational drugs still fail in clinical trials due to human toxicity unseen in pre-clinical safety assessment", said Dr. Richard Brennan, Director of Toxicology at GeneGo, "The Consortium, which includes representatives from industry and from FDA, believes that part of the problem lies in a lack of appropriate data analysis tools to prope
'/>"/>

SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...OWN, W.Va., Nov. 21 New...ng whether a smokeless, spitless tobacco product a...rchers have found that RJ Reynolds, Camel Snus - t...ction - contains surprisingly high levels of nicot... than most other snuff products," said Bruce Adkin...
(Date:11/21/2008)...A, S.C., Nov. 21 U.S. N...for Quality Assurance (NCQA) ranked BlueChoice(R) ...merica,s Best Health Plans(TM), published in U.S. ..., The respected annual ranking ranks the nation,...ber satisfaction and NCQA accreditation scores. NC...
(Date:11/21/2008)...E, N.J., Nov. 21 Barr Ph... that its shareholders overwhelmingly approved the...sition of Barr by Teva Pharmaceuticals Industries ...demonstrated the overwhelming support of the trans...wney, Barr,s Chairman and CEO. "We are pleased wit...
(Date:11/21/2008)...0 B.C., a new and deadly diseaseits cause remains ...state was teeming with citizens, soldiers and refu...rta. As streets filled with corpses, social order ... returned twice and Athens lost a third of its pop... marked the beginning of the end of the Golden Age...
Breaking Medicine News(10 mins):Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...therapeutic regimens are effective in suppressing ...nged treatment may be complicated by development o...spite // continued concerns over the safety of int... in clinical practice interrupt therapy for reason...
...te in vitro fertilization (IVF) baby of a single p...tions about the newborn's legal status and the sin... whose childless marriage had ended in divorce yea...ountry's first single father whose son was born th...
...obe University of Australia have found a new combi...he parasite responsible for causing malaria. They ...or treatment // helps in killing P. falciparum whi...hloroquine is a largely used drug in the treatment...
...most common breathing problems encountered by many...s been a considerable increase in the incidence of...as been estimated that nearly 196,000 children are...ry year with asthma attacks. A considerable amount...
Other Medicine News:Health News:A first for India - IVF baby born of surrogacy 2Health News:Improved parent-physician communication to prevent hospitalizations for childhood asthma 2
(Date:11/20/2008)..., Switzerland, November 20 /PRNewswire-FirstCall/ ...ti-infective Drugs Advisory Committee of the,U.S....o 2 against the,approval of intravenous iclaprim,...reatment of patients with complicated skin and ski...caused by methicillin-resistant Staphylococcus,au...
(Date:11/20/2008)... Calif., Nov. 20 Bionovo...ll present results from the Phase 1B,clinical tri...tatic breast,cancer, BZL101, at the Society for I...nce in Atlanta, Georgia. The Company,s oral prese...d will be presented as a part of the Best of the,...
(Date:11/20/2008)...Mass., Nov. 20 Radius Health ("Rad...onal $15 million to its second institutional finan...o $82.5 million and the total amount raised since ...sting institutional investors participated in the ...d including MPM Capital, The Wellcome Trust, Healt...
(Date:11/20/2008).... 20 PAREXEL Internation... biopharmaceutical services provider, today announ...provide regulatory consulting and clinical researc...ce, PAREXEL now has locations throughout five impo...which also include Argentina, Brazil, Chile, and M...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Mediterranean Diet May Ward Off Type 2 Diabetes 20660 1Mediterranean Diet May Ward Off Type 2 Diabetes 20660 2Mediterranean Diet May Ward Off Type 2 Diabetes 20660 3Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO 20657 1Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO 20657 2Technological Interventions Merge Into Health and Fitness 20654 1Technological Interventions Merge Into Health and Fitness 20654 2Technological Interventions Merge Into Health and Fitness 20654 3Brisk Walking Lowers Blood Pressure Increases Fitness in Obese 20651 1Brisk Walking Lowers Blood Pressure Increases Fitness in Obese 20651 2
...S WIRE)--Apr 26, 2007 - Northfield,Laboratories In...t,research organization has informed the Company t...l Phase III trauma trial with,PolyHeme(R), the Com...cell substitute, will not be complete until May., ...ories Inc. is a leader in developing an,oxygen-car...
... 0in 0pt; TEXT-ALIGN: left; tab-stops: 0in",align=...ops: list .5in; mso-list: l1 level1 lfo2">, <span ... MT,; mso-bidi-font-weight: bold">,Independent Jap...ng,Diovan to conventional therapy , , , ,<li st...so-list: l1 level1 lfo2">, <span style=,"FONT-SIZE...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 8Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 9Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 10Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 11Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 12
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products: